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Background: The purpose of this clinical study is to investigate the clinical feasibility and safety of a shuttle-based
MR-linac connection to provide MR-guided radiotherapy.
Methods/Design: A total of 40 patients with an indication for a neoadjuvant, adjuvant or definitive radiation
treatment will be recruited including tumors of the head and neck region, thorax, upper gastrointestinal tract
and pelvic region. All study patients will receive standard therapy, i.e. highly conformal radiation techniques like
CT-guided intensity-modulated radiotherapy (IMRT) with or without concomitant chemotherapy or other antitumor
medication, and additionally daily short MR scans in treatment position with the same immobilisation equipment
used for irradiation for position verification and imaging of the anatomical and functional changes during the
course of radiotherapy. For daily position control, skin marks and a stereotactic frame will be used for both imaging
modalities. Patient transfer between the MR device and the linear accelerator will be performed with a shuttle
system which uses an air-bearing patient platform for both procedures. The daily acquired MR and CT data sets will
be digitally registrated, correlated with the planning CT and compared with each other regarding translational and
rotational errors. Aim of this clinical study is to establish a shuttle-based approach for realising MR-guided radiotherapy
for certain clinical situations. Second objectives are to compare MR-guided radiotherapy with the gold standard of CT
image guidance for quality assurance of radiotherapy, to establish an appropiate MR protocol therefore, and to assess
the possibility of using MR-based image guidance not only for position verification but also for adaptive strategies
in radiotherapy.
Discussion: Compared to CT, MRI might offer the advantage of providing IGRT without delivering an additional
radiation dose to the patients and the possibility of optimisation of adaptive therapy strategies due to its superior soft
tissue contrast. However, up to now, hybrid MR-linac devices are still under construction and not clinically applicable.
For the near future, a shuttle-based approach would be a promising alternative for providing MR-guided radiotherapy,
so that the present study was initiated to determine feasibility and safety of such an approach. Besides positioning
information, daily MR data under treatment offer the possibility to assess tumor regression and functional parameters,
with a potential impact not only on adaptive therapy strategies but also on early assessment of treatment response.
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In the last decade, technological advances in medical
imaging significantly affected the specialty of radiation
oncology. Today, there is a wide range of applications
for modern imaging procedures in the oncological field
encompassing diagnosis, follow-up monitoring, progno-
sis, and assessment of functional/biological parameters
of tumor diseases as well as spatial and temporal imaging
done prior to each radiation fraction to confirm tumor
position (i.e. image-guided radiotherapy, IGRT).
In general, for radiotherapy planning a CT scan is
performed with the patient immobilized in treatment pos-
ition to define the target tissue, to calculate the irradiation
plan and to generate reference coordinates for the daily
treatment settings. Nowadays, other imaging techniques
like MRI including MR spectroscopy, PET or SPECT are
frequently used for registration to the CT planning data to
enhance tumor delineation and to display functional data
about the tumor and surrounding normal tissues [1-5]. In
particular, MRI is taken into account for radiation plan-
ning more and more frequently due to improved registra-
tion algorithms and its excellent soft tissue contrast which
allows superior distinction between cancerous and normal
tissues [6].
Furthermore, technical advances have enabled the
integration of various imaging modalities into the linear
accelerator for daily image guidance of radiotherapy, im-
proving the management of inter- and intrafractional
variations [7,8]. In particular, the use of CT for daily
image guidance marked an important milestone, which
enabled improved precision and accuracy in delivering
radiation therapy to cancerous tumors while respecting
surrounding healthy tissues and organs at risk [9-12]. By
deploying IGRT on the basis of CT image guidance,
positioning deviations can be corrected instantly and the
whole tumor volume can be assessed daily. This is very
useful since tumors can change the shape, shrink or
expand during therapy and move between treatments
due to differences in organ filling, movements while
breathing or weight loss of the patient [13-16]. In years
past, the problem of localization errors of moving
tumors during treatment was compensated by larger
planning target volumes (PTVs). This resulted in adjacent
normal tissues and critical organs receiving unnecessary
doses of radiation during treatment, which, in turn, lim-
ited the potential of dose escalation in the primary tumor
to improve treatment outcome.
Nowadays, CT-based image guidance is a standard
procedure in many radiotherapy units helping the phys-
ician to follow tumors as they move and to align the
patient to the reference position of the planning CT
dataset before each treatment session in case of gross
positional misalignments to ensure an accurate adjust-
ment of the external beam. Thus, radiation fields can beconfined to the tumor very precisely and radiotherapy
can be delivered as planned.
Generally, the use of CT-based IGRT should be
considered for the following clinical situations: Can-
cers with positional variations between the radiation
fractions to reduce geographic uncertainties, cancers
in which increased dose has been associated with in-
creased local tumor control, tumors with narrow safety
margins to dose-limiting healthy tissue structures to
achieve a steep decline outside the target (in conjunction
with intensity-modulated radiotherapy, IMRT), high con-
formal radiotherapy of intraabdominal tumors for detec-
tion of positional changes due to breathing, peristalsis or
different fillings of gastrointestinal tract, and for patients
with immobilisation problems due to pain or claustropho-
bia [11,17].
Furthermore, anatomical changes that require a modi-
fication of radiation treatment, e.g. weight loss, strong
tumor shrinkage or opening of an atelectasis, can be
assessed by IGRT at an early stage in order to take
necessary consequences, i.e. re-planning for optimized
adaptation to the aimed volume with consideration of
the new anatomical situation [16,18]. This is essential
for individual dose distributions in highly conformal
radiation therapy, with the benefits of dose escalation
in tumors and reduced side effects and thus better
tolerability.
In addition to the just mentioned benefits, there are
also some disadvantages of CT image guidance. Firstly,
CT imaging is limited with respect to achievable tissue
contrast. Secondly, existing CT solutions for IGRT (cone
beam CT, in-room CT) can not provide real time data
under treatment, so being unable for instance to follow
(irregular) breathing. Thirdly, every CT scan leads to an
additional radiation dose to the patient. This is just a
small portion of the overall radiation dose that is admin-
istered to the patient in the course of radiotherapy, but
particularly in the treatment of children and young
adults an increased risk for secondary malignancies can
not be excluded [19]. However, for the treatment of
most (elderly) patients the argument with the additional
radiation exposure is just secondary, the main argu-
ments for MRI guided radiotherapy are the much better
soft tissue contrast compared to cone beam CT, and
furthermore the option for obtaining real time data and
tracking of tumors.
The first two points particularly form the rationale for
MR-guided radiotherapy to improve delineation of the
target volume, thus saving the surrounding healthy
tissues and organs at risk, the third point for reliable
alternative imaging modalities suitable for image guid-
ance of radiotherapy that do not expose the patients to
any additional radiation dose according to the so called
ALARA (As Low As Reasonably Achievable) principle.
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feasibility and accuracy of ultrasound for image guidance
of pelvic and upper-abdominal cancers [20-23]. It is a
widely used diagnostic tool and quite inexpensive. How-
ever, as decisive disadvantages, the ultrasound procedure
is prone to interuser variability, requires experienced
personell and careful patient selection is necessary due
to the fact that good sonographic visibility of upper
abdominal cancers strongly depends from the patients’
weight, presence of intestinal gas and preparation of the
patient (empty stomach).
As a further alternative to CT, MRI may be considered
for image guidance of radiation treatment. Nowadays,
MRIs are widely available and excellent at imaging soft
tissue structures and therefore an ideal technology for
combining with linear accelerators because most cancers
occur in soft tissue. Thus, MRI is a promising and suit-
able imaging method for accurate monitoring of moving
tumors and the surrounding tissues in the everyday
practice of radiotherapy.
Two study groups from the Netherlands and Canada
could demonstrate the proof of concept of an integrated
MRI and linear accelerator [24,25]. Up to now, there are
only a few prototypes of integrated MRI-linac devices
which are still in development and not available for the
clinical routine [26]. However, first phantom results of
such MR-linac prototypes are very promising [27,28] but
it will probably take a few years until current technical
problems will be solved and such hybrid devices will be
brought to market [29-33].
That is why the concept of a shuttle-based connection
between a MRI device and a linear accelerator is a
promising alternative to provide MR-guided radiother-
apy in the near future which could be used for instance
for optimization of adaptive therapy strategies and build-
ing first experiences for real-time MRI guided radio-
therapy. Due to the fact that MR imaging in the setting
of a shuttle-based approach is off line (like existing CT
solutions for IGRT), no real time data can be provided.
However, if the uncertainties of the shuttle based
approach due to patient transport between the MRI
device and linac should remain within certain limits, this
off-line solution for MRI guided radiotherapy could be
an alternative to CT image guidance in the radiation
treatment of children or young adults. Therefore, clinical
studies are needed in order to demonstrate the feasi-
bility and safety of such an approach. In the proposed
clinical study MR-GUIDANCE (Magnetic Resonance
Tomography-guided radiotherapy compared to the gold
standard computed tomography) patients with tumors
located in the head-and-neck, thoracic, upper abdominal
and pelvic region will be enrolled receiving standard
CT-guided radiotherapy and short additional MRI
scans performed in treatment position (including allnecessary immobilization devices, treatment supports
and stereotactic tools) prior to each radiation fraction.
Besides positioning information, MRI-guided radiotherapy
offers the possibility to assess tumor regression and func-
tional parameters, with a potential impact not only on




This study is an open, mono-centric, non-randomized,
prospective study to evaluate feasibility and safety of a
shuttle-based MR-linac connection providing MR-
guided radiotherapy for position verification and imaging
of anatomical changes during the course of a radiation
treatment. Patients eligible for the MR-GUIDANCE trial
have to present with the indication for a radiotherapy of
the regions head and neck, thorax, upper abdomen and
pelvis in the neoadjuvant and adjuvant setting, or as
definitive treatment. For validation of MR-based image
guidance of radiation treatment, comparison with the
gold standard of CT will be performed on a daily basis
in the course of radiotherapy. Position correction will be
performed for all study patients entirely on the basis of
CT imaging.
Trial organisation
The MR-GUIDANCE trial has been designed by the
Departments of Radiation Oncology of the University of
Heidelberg in cooperation with the Departments of
Radiation Oncology, Diagnostic Radiology, Biostatistics
and Medical Physics at the German Cancer Research
Center (DKFZ) Heidelberg. The trial is an investigator-
initiated trial and is carried out by the Departments of
Radiation Oncology and Diagnostic Radiology at the
German Cancer Research Center together with the De-
partment of Radiation Oncology at the University Hospital
of Heidelberg.
Coordination
The trial is coordinated by the Departments of Radiation
Oncology and Diagnostic Radiology at the German
Cancer Research Center (DKFZ) in cooperation with the
Department of Radiation Oncology at the University of
Heidelberg. The Departments of Radiation Oncology at
the German Cancer Research Center and at the University
of Heidelberg are responsible for overall trial manage-
ment, database management, quality assurance, reporting
and for the scientific program of all trial related meetings.
Investigators
Patients will be recruited by the Departments of Radiation
Oncology at the University Hospital of Heidelberg and at
the German Cancer Research Center (DKFZ) Heidelberg.
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of radiation oncology.
Patient selection: inclusion criteria
Patients meeting all of the following criteria will be
considered for admission to the trial:
– Written informed consent
– Histologically confirmed tumor of the regions head
and neck, thorax, upper abdomen and pelvis
– Karnofsky performance score ≥ 70%
– Age between 18 and 80 years
– Indication for performing a definitive, neoadjuvant
or an adjuvant radiation therapy
Patient selection: exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
– Prior radiation therapy within the region planned to
be irradiated
– Decompensated secondary diseases of the
respiratory organs, cardiovascular system, metabolic
system, haematopoietic and coagulation system,
kidneys and draining urinary tract
– Contraindications against using MRI (1,5 Tesla) for
treatment planning, e.g. cardiac pacemakers and
defibrillators, artificial heart valves or cochlea
implants
– Weight ≥ 120 kg
– Claustrophobia
– Severe postoperative wound healing problems
– For tumors of the pelvis no hip prostheses
Study objectives
The main objective is to demonstrate the safety and
feasibility of MR-guided radiotherapy by using an air-
bearing transfer system for transport between a conven-
tional MRI device and a linac.
The secondary objectives are to
– compare MR-guided radiotherapy with the gold
standard of CT image guidance for position control
and imaging of anatomical changes during the
course of radiotherapy
– analyze which MR sequences are most suitable for
MR-guided radiotherapy showing the tumor and
surrounding tissues for a representative population of
different tumor sites with an acceptable compromise
between fast and reliable imaging while allowing
sufficient precision for daily position verification.
– evaluate which treatment using supports and
immobilization devices are suitable for fixation of
the patient on the platform of the shuttle system– acquire additional diffusion-weighted imaging (DWI)
data before the patient receives his or her daily
radiation therapy treatment and analyze this data to
determine whether quantitative changes of the
DWI signal can be an indicator of physiological
modifications connected to tumor response;
furthermore DWI sequences can be used for
localization, e.g. tumor or suspect lymph nodes
– acquire MR perfusion sequences at the beginning,
halfway during treatment and at the end of treatment,
in order to obtain data about the perfusion patterns of
cancerous tissues under therapy, allowing more
detailed informations about tumor regression
– assess the possibility of using MR-based image
guidance not only for quality assurance but also for
adaptive strategies in radiotherapy
Study plan
This is a single center study to compare MR-guided
radiotherapy with standard CT-guided radiotherapy.
Therefore, all eligible patients with tumors of the head-
and-neck, thoracic, upper abdominal and pelvic region
meeting all of the inclusion criteria and missing all of
the exclusion criteria will be informed about the back-
ground of this study and will be offered participation. If
the patient consented to participation in this study, the
patient will be instructed about the study plan and pro-
cedures, and the informed consent will be documented
in a written form.
All included patients will receive standard therapy, i.e.
highly conformal radiation techniques like intensity-
modulated radiotherapy (IMRT) with or without con-
comitant chemotherapy or other antitumor medication,
including daily CT image-guidance. The control CT
scans prior to every radiation session are performed on a
regular basis during the course of precision radiation
therapy for verification of patient position and monitor-
ing of anatomical changes. Therefore, no trial specific
CT imaging will be acquired and patients will not be
exposed to any additional ionizing radiation.
The only burden of the patients in this study is a MR
acquisition performed prior to every radiation fraction
in treatment position with the same immobilization
equipment used for irradiation and the prolonged time
needed for the MR scan and the transport from the MR
device to the remote linear accelerator (altogether about
15 minutes).
Position control for daily CT imaging will be provided as
standard by skin marks for exact target-point localization.
For MR imaging, MR-suitable fiducial markers will be used
allowing image registration performed under T1- and
T2-weighted MR sequences as well as under CT. These
multimodality fiducial markers will be placed exactly on
the skin marks. Furthermore, as second stereotactic
1. Patient immobilisation
2. MRI scan (about 10 min)
3. Shuttle transport from MRI device
to linac (about 5 min) 
4. Positioning on the linac table
5. CT image-guidance 
6. Position correction
7. Radiation fraction
Figure 1 Schematic depiction showing sequence of daily
imaging and radiotherapy of study patients.
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consisting of acrylic glass attached with Gadolinium filled
cables will be used for localizing of the target volume.
With the contrast agent Gadolinium stereotaxy will be
possible not only with MR images but also with CT im-
ages due to its high radiopacity. The position correction
based on the skin marks will be compared with those
based on the reference coordinates of the stereotactic
frame. If necessary, translational position correction will
be performed by a patient shift based on the contours of
soft tissue structures, i.e. particularly on the contours of
the target volume, or on the contours of bony structures.
Based on this match, the translational positioning error in
all three spatial dimensions and the necessary isocenter
shift for correction of this error will be documented. The
rotational errors will be recorded but not corrected.
The immobilisation of the study patients will be
achieved through a vacuum mattress placed within the
stereotactic body frame and in case of head and neck
cancers with an individually fabricated head mask fitting
into the head coil of the MR device.
Depending on the location or motion of the tumor,
different MR sequences for position control might be
applied, e.g. tumors of the upper abdomen require 4D-
MR sequences with high spatial and temporal resolution
with low susceptibility for motion artifacts in contrast to
more static tumors like those at the base of the skull that
primarily require appropriate anatomical imaging. The
planned MR protocol includes at least one sequence for
imaging of the anatomical structures consisting of a
T1- or T2-weighted sequence in axial direction (e.g.
T1-SE, T1-FLASH 2D, T2-TSE, T2-HASTE), eventually
combined with one balanced sequence (e.g. SSFP), and
an additional diffusion-weighted imaging (DWI) se-
quence to assess whether quantitative changes of DWI
signal might be an indicator of early tumor response
during therapy. Beside these daily native MR sequences,
intravenous application of Gadolinium is planned at the
beginning, halfway during treatment and at the end of the
treatment, in order to obtain data about the perfusion
patterns of cancerous tissues under therapy, allowing
more detailed informations about tumor regression. For
exact determination which sequence and slice thickness is
most suitable for position control and image registration
to the planning CT, a sample of applicable MR sequences
will be compared in phantom studies.
Patient transfer between the MRI device and the
remote linear accelerator will be performed with a shut-
tle system (Zephyr System, Diacor, USA). This shuttle
system is MR-compatible and uses an air-bearing tech-
nology that allows the patient to be effortlessly moved
by a transfer sled from MR scanner couch to linac
without any movement on their part as it utilises the
same patient platform with treatment using supports,immobilization devices and stereotactic tools for both
procedures. This means that the patient is scanned and
treated in the same position, minimising the risk of
translational and/or rotational positional changes during
transfer between both devices. Thus, maximum use of
image based planning data is possible.
In the following, acquired MR images will be digitally
registrated and correlated with CT planning for calcula-
tion of positioning correction vectors. For validation, the
correction vectors calculated on the basis of the MR
scans will be compared to those calculated on the basis
of the CT scans. For safety purposes, position correction
will be performed for all study patients entirely on the
basis of routinely performed and established CT data
(see Figure 1).Statistical design
Feasibility and value of pre-radiation MR imaging for
planning radiotherapy and correlation with the acquired
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will be performed. The positioning accuracy of both im-
aging modalities will be evaluated regarding translational
systematic and random errors and rotational errors in all
three spatial dimensions. Therefore, different analysis
groups will be evaluated including tumors of the head-
and-neck, thoracic, upper abdominal and pelvic region.
For optimal calculation and verification, 10 patients per
anatomic region will be analyzed, which amounts into a
total patient number of 40 patients. For assessment of
quantitative change of DWI signal during radiotherapy,
correlation with tumor response determined by regular
follow-up will be performed.
Criteria for withdrawal
Individual criteria
 Pain in supine position
 Agitated or restless patient
 Claustrophobia
 Discontinuation of study participation by the patient
General withdrawal criteria for the study
There are no general withdrawal criteria for the study
protocol.
Prior and concomitant treatments
No prior or concomitant treatment is part of this study.
All patients receive standard therapy with radiotherapy
alone or in combination with chemotherapy or other
antitumor medication in the neoadjuvant, adjuvant
setting or as definitive treatment.
Plan for treatment and care after the trial
After completion of study treatment, no further treat-
ment is planned and patients will be followed up regu-
larly. First follow-up examination will be 6–8 weeks
after the end of radiotherapy, further follow-up visits will
take place every 3 months for the first 2 years and every
6 months for 3 further years, and after 5 years in annual
intervals. They will include clinical and laboratory exam-
ination and assessment of acute and late toxicity, and if
necessary contrast-enhanced imaging with CT and/or
MRI according to the guidelines. The follow-up exami-
nations might be reduced or additional examinations,
tests and imaging might be initiated at the discretion of
the treating physicians in case of suspicion of local or
distant failure. The quantitative changes of DWI signal
during radiotherapy will be correlated with tumor
response in the follow-up.
Duration of the study
Patient accrual will start in October 2013 and the end of
accrual is planned for March 2015. After completion ofthis pilot study, all study patients will receive standard
follow-up examinations for assessment of therapy res-
ponse, clinical symptoms, toxicity and quality of life.
The end of this study is defined as the end of the last
patient’s therapy. Analysis for the primary and secondary
objectives of this study will be performed for each
anatomical region alone and finally summarized for all
regions together.
Data collection and management
All clinical and laboratory data and radiotherapy plans
will be documented by the investigators or an authorised
member of the study team in the patient’s medical
record. Important trial documents and the informed
consent forms including patients’ consent for trial par-
ticipation and application of irradiation will be stored
and archived according to §13 of the German GCP
Regulation and §28c of the German X-Ray Regulation
(StrSchV) for at least 30 years after the trial termination.
The Study Center at the Department of Radiation On-
cology will be responsible for archiving all relevant data.
Ethical and legal aspects
The study plan was approved by the Institutional Review
Board (IRB)/Independent Ethics Committee (EC) of the
Medical Faculty Heidelberg. The trial will be carried out
by adhering to local legal and regulatory requirements.
The protocol will be conducted according to the Guide-
lines of Good Clinical Practice (GCP) and the ethical prin-
ciples described in the Declaration of Helsinki in 2008.
Discussion
Since 2000, IGRT has been developed and is now been
widely introduced into clinical practice. Since this time
IGRT has made a remarkable evolution from X-ray to
different CT approaches [11]. Existing CT-based IGRT
techniques (including both off-board conventional CT
and on-board CBCT) are already very effective, but they
are limited because it is often very difficult to distinguish
tumors from normal tissues in the native contrast with
the consequence that there is further potential for plan-
ning target margin reduction which is a major concern
for adaptive therapy strategies [34]. In contrast to CT,
MRI enables a superior distinction between cancerous
and normal tissues due to its excellent soft tissue con-
trast. Thus, currently there are efforts underway to con-
struct a MRI-linac hybrid-machine [26]. In the years
past, it was a key challenge bringing the MRI and linac
systems together due to interactions between these two
devices with compromises in the performance levels
[29-31,33,35]. The dutch working group, for example,
could solve this problem through active magnetic shield-
ing and smart radiofrequency design in a diagnostic qual-
ity closed-bore system [26]. At present, major challenges
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planning and fast online image registration and tumor
tracking [27,36,37].
Furthermore, it can be assumed that such a MR-linac
hybrid-machine will be much more expensive than a
regular linear accelerator. Therefore, such hybrid-
machines will be available to only a few highly specia-
lised centres in the near future. A possible alternative
solution to a hybrid-machine could be a shuttle-based
connection between a MRI and a linear accelerator to
enable MR-guided radiotherapy. The purchase costs for
such a shuttle-system would be significantly lower than
the hybrid-machine, which makes it available for signifi-
cantly more institutions.
Moreover, such a shuttle-based solution leaves the
freedom to the physicians to use both devices independ-
ently of each other. Beyond this study, a shuttle-based
approach has the potential for a more flexible use of
other different devices, e.g. in the clinical setting of
MR-guided brachytherapy, MR-guided radiosurgery,
MR-guided particle therapy or PET-imaging after particle
therapy.
Aim of the proposed MR-Guidance pilot study is to
build first experiences for MRI-guided radiotherapy with
the chance to optimize adaptive therapy strategies, and,
if successful, to establish a shuttle-based solution for
realising MR-guided radiotherapy, and, finally, the
integration of MR-guided radiotherapy into the clinical
routine especially for the treatment of children and
young adults.
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